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Although substantial evidence supports a critical role for the activation of Raf-1 and mitogen-activated
protein kinases (MAPKs) in oncogenic Ras-mediated transformation, recent evidence suggests that Ras may
activate a second signaling pathway which involves the Ras-related proteins Rac1 and RhoA. Consequently, we
used three complementary approaches to determine the contribution of Rac1 and RhoA function to oncogenic
Ras-mediated transformation. First, whereas constitutively activated mutants of Rac1 and RhoA showed very
weak transforming activity when transfected alone, their coexpression with a weakly transforming Raf-1
mutant caused a greater than 35-fold enhancement of transforming activity. Second, we observed that coex-
pression of dominant negative mutants of Rac1 and RhoA reduced oncogenic Ras transforming activity. Third,
activated Rac1 and RhoA further enhanced oncogenic Ras-triggered morphologic transformation, as well as
growth in soft agar and cell motility. Finally, we also observed that kinase-deficient MAPKs inhibited Ras
transformation. Taken together, these data support the possibility that oncogenic Ras activation of Rac1 and
RhoA, coupled with activation of the Raf/MAPK pathway, is required to trigger the full morphogenic and
mitogenic consequences of oncogenic Ras transformation.
The three Ras proteins (H-, K-, and N-Ras) are members of
a large superfamily of regulatory proteins whose activities are
controlled by regulated GDP/GTP cycling (3, 4). Ras activity is
controlled by guanine nucleotide exchange factors (GEFs;
SOS and RasGRF/CDC25) which promote formation of active
Ras-GTP, as well as GTPase-activating proteins (GAPs; p120-
GAP and NF1-GAP), which act as negative regulators and
promote formation of inactive Ras-GDP. Whereas members of
the Ras branch of this superfamily (e.g., R-Ras and TC21/R-
Ras2) are regulators of signaling pathways that control cell
growth and differentiation (11, 16, 24, 35), Rho family proteins
control signaling pathways that regulate actin cytoskeletal or-
ganization (8, 15, 17). Rho proteins share approximately 30%
amino acid identity with Ras proteins, and their GDP/GTP
cycles are regulated by distinct Rho GAPs and GEFs (Dbl
family proteins) (3, 36). To date, at least eight distinct Rho
family proteins (RhoA, RhoB, RhoC, RhoG, Rac1, Rac 2,
TC10, and CDC42Hs) have been identified in mammalian cells
(4).
Considerable biochemical and genetic evidence suggests
that a Raf-1-triggered cascade of serine/threonine kinases is
important in mediating the mitogenic and transforming action
of Ras proteins (29, 40). Ras proteins directly bind to and
promote the activation of Raf-1, which in turn activates mito-
gen-activated protein kinase (MAPK) kinases (also designated
MEKs), which then trigger the activation of p42 and p44
MAPKs. Activated MAPKs in turn translocate to the nucleus,
where they phosphorylate and regulate the activities of nuclear
transcription factors which cause changes in gene expression
that control cell proliferation. The importance of this cascade
to oncogenic Ras transformation is supported by observations
that kinase-deficient mutants of Raf-1 and MEK can block
Ras-mediated transformation (5, 10, 27) and that constitutively
activated mutants of Raf-1 and MEK can cause malignant
transformation (10, 27, 30). Furthermore, kinase-deficient mu-
tants of MAPKs have also been shown to be inhibitors of
Ras-mediated signaling events as well as Raf-mediated trans-
forming activity (33, 45, 46). Thus, the activities of Raf and
MEKs are essential for oncogenic Ras transformation. How-
ever, whether MAPKs are also critical for Ras transformation
has not been demonstrated.
A number of experimental observations suggest that Ras
may trigger its actions via pathways which are distinct from the
Raf/MAPK pathway. For example, in addition to Raf, other
candidates for Ras effector targets have been identified. These
include the two Ras GAPs, which may function as both nega-
tive regulators and downstream targets of Ras (3, 24). Two-
hybrid yeast studies have repeatedly identified RalGDS and
RalGDS-related proteins, which function as GEFs for the Ras-
related protein Ral (1), as putative Ras effectors (21, 26, 44).
Finally, phosphatidylinositol-3-OH kinase has also been shown
to complex to Ras and to exhibit properties of a Ras effector
(41). Like Raf, these proteins show preferential binding to the
active, GTP-bound form of Ras, and this association requires
an intact Ras effector domain (Ras residues 32 to 40). How-
ever, the role of these putative Ras effectors in mediating
oncogenic Ras signal transduction and transformation is pres-
ently not known.
Recent biochemical, biological, and genetic evidence has
implicated a second Ras-mediated signaling pathway which is
distinct from the Raf/MAPK pathway and involves Rho family
proteins. First, Ridley et al. performed microinjection studies
which showed that oncogenic Ras triggered the activation of
Rac1 and RhoA in signaling pathways that regulated the actin
cytoskeleton (37, 38). Oncogenic Ras was observed to trigger
actin filament accumulation at the plasma membrane, to form
membrane ruffles via a Rac-dependent process, and to be in-
volved in actin stress fiber formation and focal adhesion de-
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velopment via a Rho-dependent process (37, 38). Activated
Rac1 was shown to trigger membrane ruffling and Rho-depen-
dent actin stress fiber and focal adhesion formation, while
activated RhoA stimulated only stress fiber and focal adhesion
formation. These observations suggested the existence of a
cascade in which oncogenic Ras induces the activation of Rac1,
which in turn activates RhoA (37, 38). However, whether these
transiently activated changes in actin organization are impor-
tant for stable Ras transformation has not been addressed.
Second, genetic studies addressing the function of the Schiz-
osaccharomyces pombe Ras homolog (ras1) showed that ras1
triggered two distinct signaling pathways (7). One involves the
byr2 serine/threonine kinase, which is homologous to Raf, and
the other involves a Rho family protein (CDC42sp) and a Rho
GEF (Scd1). Furthermore, these studies showed that scd1 di-
rectly complexed with ras1 and displayed the properties of a
downstream effector of ras1 function. Finally, White et al.
recently described results which support the existence of a Ras
effector-mediated signaling pathway which is distinct from Raf-
mediated events yet is required for full Ras transformation
(47). Taken together, these observations support a model in
which Ras function is mediated by the activities of at least two
distinct signaling pathways.
We describe results from three complementary approaches
to address the possibility that Rac1 and RhoA function down-
stream of oncogenic Ras and that their activities are required
for Ras transformation. We observed that coexpression of acti-
vated Raf with constitutively activated mutants of Rac1 and
RhoA caused a dramatic synergistic enhancement of trans-
forming activity, that dominant negative mutants of Rac1 and
RhoA inhibited oncogenic Ras transforming activity, and that
activated Rac1 and RhoA greatly potentiated oncogenic Ras-
mediated morphologic transformation. Finally, we demonstrated
that MAPK function is also required for Ras transformation.
Taken together, these observations support the proposal that
oncogenic Ras requires the coordinate activation of a Raf/
MEK/MAPK pathway and a Rac/Rho pathway for full malig-
nant transformation.
MATERIALS AND METHODS
Molecular constructs. Oligonucleotide-directed mutagenesis was used to gen-
erate mutant versions of human rac1 and rhoA (provided by A. Hall) by Taq
PCR-mediated DNA amplification approaches which we have described previ-
ously (23). The resulting mutated sequences were first verified by dideoxy se-
quencing and then introduced into the unique BamHI site in the pZIP-
NeoSV(x)1 retrovirus vector (Neor). pZIP-ras(61L) and pMUT-ras(61L) contain
cDNA and genomic sequences, respectively, that encode a highly transforming
mutant of the human H-Ras protein. The cDNA sequence encoding Raf(340D)
(provided by D. Morrison) was removed from the pBS vector (13) and inserted
into the BamHI site of pZIP-NeoSV(x)1. pfos encodes the transforming viral Fos
protein (provided by Charles Van Beveren). pCMV-based vector constructs
encoding wild-type and kinase-deficient mutant (which contain a K-to-R muta-
tion in their ATP-binding sites) human p42 and p44 MAPKs have been described
previously and were provided by M. Cobb (39).
Cell culture and transformation assays. NIH 3T3 cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% calf serum. DNA
transfections were done by the calcium phosphate precipitation technique as
previously described (9). Cells were transfected with plasmid constructs encoding
the indicated proteins at 10 ng per dish [Ras(61L)] or 2 mg per dish [Rac1(115I),
RhoA(63L), or Raf(340D)]. Transformed foci were quantitated after 14 to 16
days. Transfected cultures were stained with 0.4% crystal violet to better visualize
transformed foci. Transfected cultures were also maintained in growth medium
containing G418 at 400 mg/ml (geneticin; GIBCO/BRL) to establish cell lines
that stably expressed normal or mutant proteins. The growth properties of NIH
3T3 cells expressing wild-type or mutant Ras, Rac1, or RhoA proteins were
compared in terms of their growth rates and saturation densities on plastic, their
abilities to proliferate in low serum concentrations (1%) or soft agar (0.3%), and
their ability to form tumors when inoculated into athymic nude mice (105 cells
per site) by procedures that we have described previously (9).
The ability of Rac1, RhoA, and MAPK mutant proteins to modulate Ras(61L)
or Fos focus-forming activity was determined by cotransfection focus inhibition
assays by procedures similar to those that we have previously described for Raf
dominant negative proteins (5). Cultures were transfected with either pMUT-1
plasmid DNA (10 ng per dish), pfos plasmid DNA (500 ng per dish) alone, or
pfos plasmid DNA (500 ng per dish) plus plasmid DNA expression vectors
encoding either wild-type or mutant Rac1, RhoA, or MAPK proteins. The
appearance of transformed foci was quantitated after 14 to 16 days. Relative
focus-forming units were calculated on the basis of the number of transformed
foci present in control dishes, which were transfected with empty pZIP-
NeoSV(x)1 retrovirus vector [4 3 103 to 6 3 103 foci per mg of transfected
ras(61L) plasmid DNA]. Data shown are representative of two or more inde-
pendent determinations, with each determination representing the average num-
ber of foci from four dishes.
Protein expression. Protein expression from the exogenously introduced ras,
rac1, or rhoA cDNA sequences were determined by Western immunoblot anal-
yses of G418-selected cell lysates. H-Ras expression was determined with the
146-3E4 mouse anti-H-Ras monoclonal antibody (Quality Biotech). RhoA ex-
pression was determined with the RhoA (119) rabbit anti-RhoA polyclonal
antiserum, which recognizes RhoA residues 119 to 132 but does not recognize
the closely related RhoB or RhoC proteins (Santa Cruz Biotechnology). Rac1
expression was determined with the Rac1 (C-11) rabbit polyclonal antiserum,
which recognizes the Rac1 C terminus but does not recognize Rac2 or other
Ras-related proteins (Santa Cruz Biotechnology). Antibody was detected by
enhanced chemiluminescence (Amersham).
Transient-transfection CAT assays. To compare the ability of Ras, Rac1, or
RhoA proteins to induce transcriptional activation of Ras-responsive promoter
elements, NIH 3T3 cells were transiently cotransfected with 0.5 mg of plasmid
DNA encoding mutant Ras or 5 mg of plasmid DNA encoding normal or mutant
Rac1 or RhoA proteins together with 1 mg of the pB4X-CAT reporter plasmid
(provided by B. Wasylyk) (6). This reporter plasmid contains the chloramphen-
icol acetyltransferase (CAT) gene driven by a minimal promoter that contains
four tandem copies of the Ras-responsive promoter element from the polyoma-
virus enhancer (ets/AP-1 sequences). At 48 h after transfection, cell lysates were
prepared, and the CAT activity induced by each ras, rac1, or rhoA construct was
assayed as described previously (20).
MAPK activation. Activation of the MAPK pathway in NIH 3T3 cells express-
ing Ras(61L), Rac1(115I), or RhoA(63L) was determined essentially as de-
scribed previously (46). Briefly, total-cell extracts were prepared in Laemmli
sample buffer, resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, and transferred to Immobilon membranes (Millipore) for analysis by
Western blotting with the 691 anti-MAPK antiserum (Santa Cruz Biotechnology)
to detect the phosphorylated active and nonphosphorylated inactive forms of
p42MAPK/ERK2 and p44MAPK/ERK1.








Ras(WT) Wild type 1 0.00 0/4
Ras(61L) 61 (Gln3Leu) 1 1.00 4/4
Ras(116I) 116 (Asn3Ile) 1 0.22 3/3
Rac1(WT) Wild type 1 0.00 0/6
Rac1(61L) 61 (Gln3Leu) NDd 0.00 ND
Rac1(115I) 115 (Asn3Ile) 1 0.00e 6/6
RhoA(WT) Wild type 1 0.00 0/6
RhoA(63L) 63 (Gln3Leu) 1 0.01 6/6
RhoA(117I) 117 (Asn3Ile) ND 0.00 ND
a Expression of exogenously introduced ras, rac1, and rhoA cDNAs was deter-
mined by Western blot analysis as described in Materials and Methods. Whereas
we found that untransfected NIH 3T3 cells showed very low (6; H-Ras and
Rac1) or no (2; RhoA) detectable levels of endogenous protein, we readily
detected severalfold-higher levels (1) of protein expression in the stably trans-
fected mass populations.
b Focus-forming activities in NIH 3T3 transfection assays were normalized to
the activities observed with Ras(61L) (4 3 103 to 6 3 103 foci per mg of plasmid
DNA 5 focus-forming units).
c Number of animals positive for tumor growth/number of animals inoculated.
Data are from two independent assays. Ras(61L)-transformed cells formed large
tumors (;1 cm in diameter) after 1 to 2 weeks, whereas Rac1(115I)- and
RhoA(63L)-transformed cells caused large tumors (;1 cm in diameter) after 10
to 12 weeks.
d ND, not determined.
e Rac1(115I) showed focus-forming activity only after G418 selection of trans-
fected cells.
6444 KHOSRAVI-FAR ET AL. MOL. CELL. BIOL.
Cell motility analysis. NIH 3T3 cells stably expressing the indicated proteins
were plated at low density onto 60-mm tissue culture dishes and incubated
overnight in growth medium. The growth medium was then removed and re-
placed with serum-free medium. Cell movement was then recorded with a time-
lapse video recorder with a 60-fold time compression. The rates of cell motility
were calculated by measuring the displacement of individual cells at 378C at
10-min intervals over a 1-h period. Rates are reported as an average of values for
at least 20 samples.
RESULTS
Constitutively activated mutants of Rac1 and RhoA exhibit
weak focus-forming activity in NIH 3T3 cells. Our first ap-
proach to defining the contribution of Rac1 and RhoA func-
tion to Ras transforming activity was to determine the biolog-
ical consequences of constitutive Rac1 and RhoA activities in
NIH 3T3 cells. For these studies, we generated mutant versions
of these two Rho family proteins which contained single amino
acid substitutions analogous to those that activate Ras trans-
forming potential (Table 1). Ras(61L) and Ras(116I) are con-
stitutively activated mutants as a consequence of impaired
intrinsic and GAP-stimulated GTPase activities or greatly en-
hanced GDP-GTP exchange rates, respectively. The trans-
forming potentials of the Rac1 and RhoA mutants were then
compared with those of constitutively activated forms of Ras in
NIH 3T3 focus formation assays.
As described previously (11a), Ras(61L) showed potent fo-
cus-forming activity when transfected at 10 ng of plasmid DNA
per dish (.4 3 103 foci per mg). In contrast, we observed no
focus-forming activity when plasmid constructs encoding wild-
type or mutant Rac1 proteins were transfected at concentra-
tions of up to 2 mg of DNA per dish (Table 1). Similarly, no
focus-forming activity was observed in cultures transfected
with vectors encoding RhoA(WT) or RhoA(117I). However,
we did observe a very low frequency of transformed foci in
cultures transfected with pZIP-rhoA(63L). This activity was
approximately 60-fold lower than that observed with Ras(61L),
and the appearance of RhoA(63L)-induced foci was very dis-
tinct from that of Ras(61L)-induced foci (Fig. 1A). Whereas
Ras(61L) caused the appearance of foci which had a swirled
appearance and contained very refractile, elongated, spindle-
shaped cells, RhoA(63L)-induced foci were more compact and
consisted of densely packed cells that were not very refractile
in appearance.
Although initially we saw no focus-forming activity for any of
the Rac1 mutant proteins, we did observe the appearance of
transformed foci from NIH 3T3 cells stably expressing the
Rac1(115I) mutant. These transformed foci appeared in cul-
tures of cells which were plated from pooled populations of
G418-resistant colonies after transfection with pZIP-rac1
(115I). Rac1(115I)-induced foci showed a similar appearance
to RhoA(63L)-induced foci (Fig. 1A). Because these trans-
formed foci occurred after only one passage of the G418-
resistant colonies, we suspect that these morphologically trans-
formed subpopulations may represent cells that express higher
levels of the mutant Rac1 protein rather than cells that had
acquired secondary changes to complement Rac1(115I) activ-
ity. Rac1(115I) focus-forming activity was comparable to the
FIG. 1. Aberrant Rac1 and RhoA function causes transformation of NIH 3T3 cells. (A) Rac1(115I)- and RhoA(63L)-induced foci are distinct from Ras(61L)-
transformed foci. (B) Rac1(115I)- and RhoA(63L)-transformed NIH 3T3 cells form colonies in soft agar. Colonies from Ras(61L)-transformed cells are shown after
10 days, whereas colonies from Rac1(115I)- or RhoA(63L)-transformed cells are shown after 30 days. Ras(61L)-transfected cells showed 5 to 10% colony-forming
efficiency, whereas Rac1(115I)- and RhoA(63L)-transfected cells showed 0.1 to 0.5% and 0.5 to 1% frequencies, respectively.
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potency that we have observed for previously described trans-
forming mutants of MEK (10, 30).
Expression of activated Rac1(115I) and RhoA(63L) en-
hances the growth of NIH 3T3 cells. The weak focus-forming
activity observed with Rac1(115I)- and RhoA(63L)-transfected
cultures suggested that these two mutant proteins altered the
growth properties of NIH 3T3 cells. To evaluate this possibil-
ity, we compared the in vitro and in vivo growth properties of
cells expressing either wild-type or mutant versions of these
two proteins with Ras(61L)-transformed cells. To avoid clonal
variations in our analyses, we used pooled populations of mul-
tiple G418-resistant colonies (.100 colonies), rather than iso-
lated transformed foci, for the different biological assays. Par-
allel cultures of NIH 3T3 cells stably transfected with the
empty pZIP-NeoSV(x)1 vector or pZIP-ras(61L) were also
established and used as control cell lines for these analyses.
Protein expression from the exogenously introduced ras, rac1,
and rhoA cDNAs was confirmed by Western blot analysis and
showed levels which were severalfold above the endogenous
levels (Fig. 2A; Table 1).
Cells stably expressing Rac1(115I) or RhoA(63L) did not
exhibit the same morphologic transformation observed with
Ras(61L)-transformed cells. Instead, these cells retained the
poorly refractile and highly adherent properties which are
characteristic of untransformed NIH 3T3 cells. In contrast, we
observed that like Ras-transformed cells, cells stably express-
ing Rac1(115I) or RhoA(63L) formed colonies in soft agar
(Fig. 1B), displayed increased growth rates and saturation den-
sities (Fig. 2B), and proliferated in low serum concentrations
(1%) (data not shown). However, Ras(61L)-transformed cells
typically showed more enhanced growth potential than did
either Rac1(115I)- or RhoA(63L)-transformed cells in each of
these growth assays. For example, whereas Ras(61L)-trans-
formed cells formed large soft agar colonies within 2 weeks,
Rac1(115I)- and RhoA(63L)-transformed cells formed smaller
colonies after 4 weeks. Our observations with RhoA(63L)-
transformed cells are consistent with previous observations
that RhoA exhibits weak transforming potential (2, 34, 42).
We also evaluated the ability of the different cell populations
to form tumors when inoculated into athymic nude mice (Ta-
ble 1). As described previously, Ras(61L)-expressing cells
showed progressive tumor formation (;1 cm in diameter)
within 1 to 2 weeks whereas Ras(WT)-expressing cells failed to
show any tumor formation for up to 8 weeks (11, 16). RhoA
(63L)- and Rac1(115I)-expressing cells formed progressive tu-

































A. FIG. 2. Cells expressing normal and mutant Rac1 and RhoA proteins showenhanced growth rates and saturation densities. (A) Expression of wild-type and
mutant Rac1 and RhoA proteins in pooled populations of G418-selected NIH
3T3 cells which were transfected with pZIP constructs encoding the indicated
protein. (B) Cells stably transfected with vector constructs expressing the indi-
cated protein were plated 105 cells per 60-mm dish on day 1, and the number of
cells per dish was determined on days 3, 5, 7, and 9. Numbers represent the
average of duplicate dishes.
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transfected with the empty-vector control remained negative
for tumor growth for up to 12 weeks. Thus, like Ras(61L), both
Rac1(115I) and RhoA(63L) enhanced growth potential and
caused malignant transformation of NIH 3T3 cells. Finally, our
observation that tumor-derived cell lines showed higher ex-
pression of Rac1(115I) and RhoA(63L) is consistent with a
transforming action of these two mutated proteins (data not
shown).
Constitutively activated mutants of Rac and Rho are not
activators of the Raf/MAPK pathway. Since it has been shown
that Rac1 and RhoA function downstream of Ras (37, 38), we
determined whether constitutively activated forms of these
proteins could trigger downstream signaling events associated
with oncogenic Ras-mediated activation of the Raf/MAPK
pathway. Oncogenic but not normal Ras can activate transcrip-
tion from reporter plasmids that contain Ras-responsive pro-
moter elements upstream of the CAT gene (20), and dominant
negative mutants of Raf and MAPKs can block this activity (5,
46). For these analyses, we used a reporter plasmid in which
CAT gene expression is regulated by a minimal promoter
which contains the ets/AP-1 Ras-responsive promoter in tran-
sient-transfection assays. Whereas oncogenic Ras(61L) caused
a 4- to 13-fold activation of transcription, no activation was
observed with wild-type or mutant versions of rac1 or rhoA
genes (data not shown). Finally, we also determined whether
Rac1(115I)- or RhoA(63L)-transformed cells possessed the
constitutively activated levels of p42 and p44 MAPKs that we
and others have observed in Ras-transformed NIH 3T3 cells
(11, 16, 22). In contrast to Ras(61L)-transformed cells, neither
RhoA(63L)- nor Rac1(115I)-transformed cells showed signif-
icant levels of activated MAPKs (data not shown). Thus, both
Rac1 and RhoA may cause transformation via pathways which
are distinct from the Ras-activated Raf/MAPK pathway.
Dominant negative mutants of Rac1 and RhoA inhibit Ras
transformation. If Rac1 and RhoA activation is required for
Ras transforming activity, we anticipated that blocking the
functions of Rac1 and RhoA should impair Ras-mediated
transformation. Consequently, we generated dominant inhibi-
tory mutants of these two proteins, analogous to the Ras(17N)
dominant inhibitory protein (14), designated Rac1(17N) and
RhoA(19N). Rac1(17N) has previously been shown to function
as a dominant negative inhibitor of Rac function (38). NIH
3T3 cells were then transfected with expression constructs of
Ras(61L), either alone or together with Rac1(17N) or RhoA
(19N). Whereas cultures transfected with Ras(61L) alone
caused the appearance of more than 60 transformed foci per
dish, cotransfection with the Rac1 and RhoA mutants caused
an approximately 50% reduction in transformed foci (Fig. 3A).
This degree of inhibition is comparable to the inhibition seen
with the well-characterized Raf301 dominant negative mutant
(Fig. 3A) (5). The incomplete inhibition seen with the Raf,
Rac1, and RhoA dominant negative mutants reflects in part
their incomplete cotransfection into all cells that acquire Ras
and in part the likelihood that each dominant negative mutant
alone will impair only a subset of the multiple signaling events
required for full Ras transforming activity.
Finally, we observed that NIH 3T3 cells stably expressing
Ras(61L) and either Rac1(17N) or RhoA(19N) (Fig. 4A) showed
a partial reversion of the morphologic transformation caused
by the expression of Ras(61L) alone (Fig. 4B). Similar to un-
transformed NIH 3T3 cells, these coselected cells lacked the
spindle-shaped, highly refractile morphology of Ras(61L)-trans-
formed cells. The partial inhibition of Ras transformation may
reflect the likelihood that Rac1 and RhoA dominant negative
mutants will impair only a subset of signaling events required
for full Ras transformation. Nevertheless, these results are
consistent with the focus inhibition data and suggest that Rac1
and RhoA activities are required for full Ras transforming
activity.
MAPKs are essential for oncogenic Ras transforming activ-
ity. Our observations with Rac1 and RhoA suggested that a
Ras-mediated signaling pathway involving these Ras-related
proteins, together with the Raf/MAPK pathway, is required for
full Ras transformation. However, although constitutively ac-
tivated MAPKs are observed in Ras-transformed NIH 3T3
cells (11, 16, 22), it has not been established whether their
activities are required for full oncogenic Ras transformation.
We and others have previously shown that kinase-deficient
mutants of p42 and p44 MAPKs can function as dominant
inhibitory proteins and block Ras-mediated signal transduction
FIG. 3. Requirement for Rac1, RhoA, and MAPKs for Ras or Raf transformation. (A) Dominant negative mutants of Rac1 and RhoA reduce Ras(61L)
focus-forming activity. NIH 3T3 mouse fibroblasts were transfected with 50 ng of pMUT-1 DNA [encoding RasH(61L)] per dish, either alone or together with 1 mg
of pZIP-NeoSV(x)1 expression constructs of dominant negative Rac1(17N), RhoA(19N), or Raf301. (B) Cotransfection of kinase-deficient but not wild-type MAPKs
causes inhibition of Ras(61L) focus-forming activity. (C) RhoA(63L) and Rac1(115I) potentiate oncogenic Ras(61L) focus formation.
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and Raf transforming activity (33, 45, 46). To extend these
observations, we performed cotransfection studies to deter-
mine if coexpression of kinase-deficient MAPKs can inhibit
Ras transformation. Whereas cotransfection with expression
vectors encoding wild-type p42 or p44 MAPKs did not reduce
Ras(61L) focus-forming activity, cotransfection with either ki-
nase-deficient p42(52R) or p44(71R) caused a 50% reduction
in Ras(61L)-induced focus-forming activity (Fig. 3B). This de-
gree of inhibition is comparable to what we and others have
seen with kinase-deficient Raf dominant negative proteins. Fi-
nally, no reduction in the number of G418-resistant colonies or
reduction in v-fos focus-forming activity was observed in NIH
3T3 cultures transfected with expression vectors encoding
these mutant MAPKs. Thus, the reduction in Ras focus for-
mation is not likely to be a consequence of a nonspecific
inhibitory action. These results suggest that oncogenic Ras
activation of the Raf/MAPK pathway, as well as Rac1 and
RhoA, is required for full Ras transformation.
Coordinate expression of activated Rac1 or RhoA with Raf
causes synergistic enhancement of transforming activity. Our
observation that dominant negative mutants of Rac1 and
RhoA, as well as MAPKs, blocked Ras focus-forming activity
suggested that the coordinate activation of a Raf/MAPK and a
Rac/Rho pathway may be required for full oncogenic Ras
transforming activity. If this is so, we anticipated that the co-
ordinate expression of activated Raf, together with activated
Rac1 or RhoA, may cause a synergistic enhancement of trans-
formation. For these experiments, we used a weakly transform-
ing mutant of human c-Raf-1, designated Raf(340D) (13). The
Raf-1 tyrosine residue at position 340 is phosphorylated in
response to the activation of various activated tyrosine kinases,
and the substitution of a charged residue (Y340D) at this
position has been shown to activate Raf transforming potential
(13).
For these assays, expression plasmids for Rac1(115I), RhoA
(63L), or Raf(340D) were transfected at DNA concentrations
that resulted in very low or no focus-forming activity (Fig. 5).
However, we observed that cotransfection of either Rac1(115I)
or RhoA(63L) with Raf(340D) resulted in a dramatic enhance-
ment of focus-forming activity. Coexpression of Rac1(115I)
with Raf(340D) resulted in the appearance of more than 20
foci per dish, whereas parallel dishes transfected with either
alone did not show any transformed foci (Fig. 3C and 5).
Similarly, the very weak focus-forming activity observed with
RhoA(63L) alone was enhanced more than 35-fold when it was
cotransfected with nontransforming levels of Raf(340D) (Fig.
5). These results are consistent with a model in which onco-
genic Ras requires the coordinate activation of a Raf- and a
Rho-mediated pathway for full transforming potential.
Activated Rac1(115I) and RhoA(63L) enhances oncogenic
Ras(61L) morphologic transformation. To evaluate the con-
tribution of activated Rac1 and RhoA to the transformed phe-
notype of oncogenic Ras-expressing cells, we determined if the
coordinate expression of activated Rac1(115I) or RhoA(63L)
would further enhance any properties of oncogenic Ras-trans-
formed cells. First, although Ras(61L) already showed potent
focus-forming activity, we observed that cotransfection of ac-
tivated Rac1(115I) or RhoA(63L) caused a 70 to 100% en-
hancement of Ras(61L) focus-forming activity (Fig. 3C). We
also found that the appearance of the transformed foci was
dramatically altered in these cotransfection assays. Whereas Ras
(61L)-induced foci contained very refractile, spindle-shaped
cells, cotransfection with either Rac1(115I) or RhoA(63L)
caused the appearance of the transformed foci was dramati-
cally altered in these cotransfection assays. Whereas Ras(61L)-
induced foci contained very refractile, spindle-shaped cells,
cotransfection with either Rac1(115I) or RhoA(63L) caused the
appearance of transformed foci that contained very rounded,
refractile, and poorly adherent cells (Fig. 6A and B). These
striking alterations in cell morphology were unexpected in light
of the fact that we saw only limited alterations in cell morphol-
ogy in cells transformed by either Rac1(115I) or RhoA(63L)
alone.
We also determined the consequences of Rac1(115I) or
B
FIG. 4. Coexpression of Rac1(17N) and RhoA(19N) decreases oncogenic
RasH(61L)-induced morphologic transformation. NIH 3T3 cells were trans-
fected with 2 mg of pMUT-1 (Neos) and 50 ng of pZIP-Rac1(17N) or pZIP-
RhoA(19N) (both Neor). Similar to the potent growth-inhibitory activity of the
Ras(17N) dominant negative mutant, only rare G418-resistant colonies were
detected in drug-selected NIH 3T3 cells transfected with the Rac1(17N) or
RhoA(19N) expression vectors, indicating that both mutant proteins were also
growth inhibitory (results not shown). Therefore, isolation of G418-resistant
colonies was observed only when these expression constructs were cotransfected
with the Neor Ras(61L) expression plasmid. (A) Transfected cells were main-
tained in growth medium supplemented with 400 mg of geneticin (G418) per ml
to select for the cells that are expressing Ras(61L) and the dominant negative
mutant proteins. Western blot analysis showed expression of dominant negative
Rac1(17N) and RhoA(19N) proteins in cells which coexpress oncogenic
RasH(61L). Lanes: 1, vector only; 2, Ras(61L); 3, Ras(61L) plus RhoA(19N); 4,
Ras(61L) plus Rac1(17N). (B) Approximately 30% of the cotransfected cells
showed a flatter, less refractile morphology. Shown is a representative clonal
population of cells which coexpress Ras(61L) and the indicated dominant neg-
ative protein.
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RhoA(63L) coexpression on the properties of Ras-trans-
formed cells. First, we observed that their coexpression en-
hanced the frequency, size, and appearance of Ras(61L)-trans-
formed colonies in soft agar (Fig. 6C). In particular, whereas
colonies formed by Ras-transformed cells were round clusters
that possessed a smooth and uniform surface, cells coexpress-
ing either Rho family protein showed uneven surfaces that
contained extensions which suggested that they exhibited an
enhanced ability to migrate. Consistent with this, we observed
that cells coexpressing Rac1(115I) and Ras(61L) showed
greater motility than did cells expressing either protein alone
(Fig. 6D). Finally, time-lapse video analysis showed that cells
coexpressing Rac1(115I) and Ras(61L) displayed significantly
more membrane-ruffling activity than did cells transformed by
either protein alone (data not shown). Thus, constitutive acti-
vation of Rac1 and RhoA greatly potentiated several aspects of
the transformed phenotype of Ras-transformed cells.
DISCUSSION
Observations from several independent lines of study sug-
gest that oncogenic Ras may mediate its actions through a
Raf-independent pathway that involves members of the Rho
family of Ras-related proteins. First, microinjection studies
showed that both Rac and Rho functions are required for
oncogenic Ras-mediated changes in the actin cytoskeleton (37,
38). Second, genetic studies have implicated a second Ras-
mediated pathway, involving Rho family proteins, which con-
trols cell morphology in S. pombe (7). Third, random-mutagen-
esis studies identified a mutant of Ras that no longer bound
Raf but still retained an activity required for Ras transforming
potential (47). In the present study, we observed that dominant
inhibitory mutants of Rac1 and RhoA blocked oncogenic Ras
transforming activity whereas weakly transforming mutants of
Rac1 and RhoA cooperated with a weakly transforming mu-
tant of Raf-1 and caused potent transforming activity; we also
observed that activated Rac1 and RhoA further enhanced on-
cogenic Ras-mediated morphologic transformation and cell
motility. These results provide further support for a Ras-trig-
gered activation of a Rho-mediated signaling pathway and
demonstrate an important contribution of Rac- and Rho-in-
duced changes in the actin cytoskeleton to oncogenic Ras
transformation of NIH 3T3 cells. Since we also observed that
kinase-deficient MAPKs mutants inhibited Ras transforma-
tion, we propose that oncogenic Ras activation of the Raf/
MAPK pathway and of a Rac/Rho pathway may together be
required for the mitogenic and morphogenic events associated
with Ras transformation (Fig. 7).
Although our observations that Rac1 and RhoA activities
can modulate Ras and Raf transforming activities may simply
reflect the complementary actions of two independent signal-
ing pathways, these results are consistent with the observations
from microinjection and yeast genetic studies and support a
model that Rac and Rho are downstream mediators of onco-
genic Ras transformation. Furthermore, we have recently
observed that two effector domain mutants of oncogenic Ras
that are defective for interaction with Raf (47) and MAPK
activation retain transforming activities similar to those of ac-
tivated Rac1 and RhoA proteins (25). We have also observed
that coexpression of activated Raf(340D) restored Ras-like
transforming activities to these transformation-impaired Ras
mutants (25). These observations support the possibility that
oncogenic Ras can activate Rho family proteins via a down-
stream, effector-mediated process.
Presently, it is not clear how oncogenic Ras might regulate
Rac1 and RhoA function. However, the identification of Ras
effector targets which are distinct from Raf suggests the pos-
sible presence of linkages between Ras and these Ras-related
proteins. Like Raf, p120-GAP, NF1-GAP, RalGDS and re-
lated proteins, and PI3K all show preferential binding to the
FIG. 5. Cotransfection of activated Rac1(115I) or RhoA(63L) with activated Raf(340D) causes synergistic enhancement of focus-forming activity. Whereas
transfection of 1 mg of pZIP-raf(340D), which encodes a weakly transforming Raf mutant protein (13), alone showed no focus-forming activity, cotransfection with
constitutively activated Rac1(115I) or RhoA(63L) showed greatly enhanced focus-forming activities. Cultures transfected with either Rac1(115I) or RhoA(63L) showed
no and low focus-forming activity, respectively. Representative dishes were stained with crystal violet to visualize transformed foci.
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activated, GTP-complexed form of Ras, and this binding is
impaired by mutations in the Ras effector domain (3, 21, 26,
41, 44). Thus, Rac1 and RhoA may be activated via Ras inter-
action with one of these putative downstream effectors. For
example, studies by McGlade et al. indicated that p120-GAP
may link Ras with pathways that control the actin cytoskeleton
(31). They observed that overexpression of a truncated form of
p120-GAP, which lacked the GTPase-activating domain, caused
alterations in the actin cytoskeleton and cell morphology. This
linkage may be a consequence of the p190 GAP-associated
protein, which functions as a Rho GAP (43). Similarly, phos-
phatidylinositol-3-OH kinase has been shown to be an up-
stream activator of Rho family proteins and may link the Ras
and Rho pathways (28, 48). We are presently evaluating the
possible connection between different Ras effectors and the
functional interaction between oncogenic Ras and Rho family
proteins.
A second possible connection between Ras and Rho pro-
teins may be fostered by proteins that coordinately regulate
Ras and Rho activities. In addition to the GAP-associated
p190 protein, which may coordinately regulate the GTPase
activities of Ras and Rho proteins (32, 43), Ras GEFs may
function as bifunctional proteins that coordinately activate Ras
and Rho proteins. In addition to CDC25-homologous domains
required for Ras GEF activity, both SOS and RasGRF/CDC25
contain sequences which show strong amino acid identity with
the protein encoded by the dbl oncogene (36). Dbl has been
shown to function as a GEF for several members of the Rho
branch of the Ras superfamily (RhoA and CDC42Hs) (18, 19),
and its transforming activity is consistent with constitutive ac-
tivation of Rho proteins (22). Thus, while no Rho GEF activity
has presently been described for the Dbl homology domains of
SOS or RasGRF/CDC25 (36), it remains possible that these
proteins can coordinately regulate the activities of Ras and
Rho family proteins. Finally, a third possible connection may
be a consequence of an oncogenic Ras-triggered autocrine loop,
via upregulation of transforming growth factor a, to trigger cell
surface receptor-mediated activation of signaling pathways
that lead to the activation of Rho family proteins. This possi-
bility is supported by the observation that various growth fac-
tors trigger Rac- and Rho-dependent membrane ruffling and
stress fiber formation (38).
Our observation that coexpression of activated Rac1 and
RhoA with oncogenic Ras resulted in highly refractile, poorly
adherent cells supports a role for these two Rho family pro-
teins in mediating oncogenic Ras-triggered morphologic trans-
formation. However, these results contrast with observations
that the transient consequences of Rac1 and RhoA activation
are to promote the development of actin stress fibers and the
formation of focal adhesion contacts (37, 38). Furthermore, we
previously observed that RhoA-transformed cells do not show
the same disruption in cell morphology associated with Ras-
transformed cells but instead show an enhancement of actin
stress fibers and focal adhesions (22). One possible explanation
for these apparently contrasting actions of Rac1 and RhoA
may be that the chronic activation of these two proteins, in the
context of other Ras-mediated signaling events, may lead to a
disruption, rather than a promotion, of the actin cytoskeleton
and focal adhesions. Alternatively, the aberrant overexpression
of Rac1 and RhoA activities may simply deregulate the inter-
actions of actin structures with other cytoskeletal components,
thereby leading to a loss of cytoskeletal organization.
While the combined observations from microinjection stud-
ies, yeast genetic analyses, and Ras transformation studies sup-
port the existence of a Ras-mediated signaling pathway involv-
ing Rho family proteins, more evidence is clearly required to
confirm the model proposed in Fig. 7. For example, although
genetic studies support the divergence of these two pathways at
the level of Ras (7), the potent morphologic transformation
FIG. 7. Oncogenic Ras coordinately activates the Raf/MAPK and Rac/Rho
pathways. From the combined observations in previous studies and the present
study, it appears that oncogenic Ras transforming activity is mediated by at least
two distinct signaling pathways.
FIG. 6. RhoA(63L) and Rac1(115I) enhance the transformed properties of
oncogenic Ras(61L)-transformed cells. Coexpression of RhoA(63L) or Rac1
(115I) enhanced the morphologic transformation of Ras(61L)-induced foci (A)
as well as the appearance of individual cells (B), the number and appearance of
colonies in soft agar (day 20) (C), and cell motility (D). NIH 3T3 mouse fibro-
blasts were transfected with 50 ng of pMUT-1 DNA [encoding RasH(61L)] per
dish, either alone, or together with 1 mg of pZIP-NeoSV(x)1 expression con-
structs of constitutively activated Rac1(115I) or RhoA(63L).
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associated with constitutively activated mutants of Raf-1 ar-
gues against a divergence of a Rac/Rho pathway at the level of
Ras effector interaction. Like the remarkable convergence of
observations from biochemical and biological studies of mam-
malian cells, together with genetic studies of Caenorhabditis
elegans, Drosophila melanogaster, and yeasts, that established
the now well-defined Ras3Raf3MEK3MAPK pathway (12,
24, 35), further studies are required to provide a clear delin-
eation of the mechanism by which Rho family proteins mod-
ulate Ras signal transduction and transformation. Neverthe-
less, it is becoming increasingly clear that Ras proteins do not
simply function in a single linear signaling pathway which con-
nects the cell surface with the nucleus and that Ras function
will be mediated by multiple signaling pathways.
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